Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Geron Corp. -- Ignore unavailable to you. Want to Upgrade?

To: freelyhovering who wrote (1271)	11/7/1998 3:57:00 AM
From: scaram(o)uche	Read Replies (3) \| Respond to of 3576

Myron: You can imagine how much I'm kicking myself for not jumping at the opportunity. Again.... your "here are the facts" post provided many individuals who only look at the biotech threads to profit along with you. I was pretty busy today in any event; The profit potential in selected near-the-money calls was close to that in GERN. OSIP is also a nice part of my portfolio, and I was busy trading it, both on paper here at SI and in the real world. Here's a taste of biotech's week........ exchange2000.com and of the day's confusion/fun regarding OSIP..... exchange2000.com It's hard to estimate where the stock should settle. At this moment, research premiums, the differential between cash and market caps, are pretty skimpy. On the other hand....... (1) third-tier has been irrationally beaten down for twelve months, (2) ENMD has retained a bit more of its ooooomph than I would have expected, indicating a tendency to return to a frame of reference where a more rational premium is paid for a good research infrastructure and patents, and (3) some of the hype today was justified......... pharma executives all over the world were asking themselves "should I try to get us involved with this?" Then I think of Neurex and the fact that acquisitions in the sector usually command a hefty premium. I had a chance to interact, close business discussions, with Tom Okarma when he was CEO of AIS and I was directing a monoclonal group at Cutter (Bayer). Class act. He [barely] pulled AIS through a really tough funding window, and eventually got his shareholders a very good deal. This was one of biotech's tightest squeezes. We all thought AIS was "gonners". :-) He also licensed the Becton Dickinson/Johns Hopkins patent that CellPro elected to fight. Thanks again. Rick